Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanofi is dropping plans for its own mRNA-based COVID-19 vaccine because of the dominant role of the BioNTech-Pfizer alliance as well as Moderna in the fight against the pandemic, the company said on Tuesday.

Sanofi ditches mRNA COVID-19 vaccine amid rivals' success

Sanofi said Tuesday that it recorded positive interim results from an early study into its first mRNA-based Covid-19 vaccine candidate.

Sanofi reports encouraging early results for COVID-19 mRNA vaccine candidate

Sanofi announces p ositive Phase 1/2 study interim results for its first mRNA-based vaccine candidate

Sanofi announces positive Phase 1/2 study interim results for its first mRNA-based vaccine candidate

Sanofi SA (NASDAQ:SNY) shares traded higher by 0.4% on Monday after the company scored an analyst upgrade. The Analyst: SVB Leerink analyst Geoffrey Porges upgraded Sanofi from Market Perform to Outperform and raised his price target per U.S. ADR from $69.61 to $71.37.

Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism

British American Tobacco

Diageo

Novartis

Unilever

With September and the third quarter almost over, many investors are looking to the fourth quarter and beyond.

5 European Dividend Aristocrats Offer Huge Income and Growth Potential

Availability of the Q 3 202 1 Memorandum for modelling purposes

Sanofi: Availability of the Q3 2021 Memorandum for modelling purposes

Sanofi is a leading global healthcare company from France. 2021 results are strong, and FY 2021 guidance lifted.

Sanofi: A Wonderful Company At A Fair Price

Kadmon Hlds

NEW ORLEANS, Sept. 21, 2021 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.

KADMON HOLDINGS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kadmon Holdings, Inc. - KDMN

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen.  According to data released at the European Society for Medical Oncology 2021 ( ESMO21 ), Libtayo, used on top of platinum doublet chemotherapy, reduced the risk of death by 29% over chemo alone in patients with previously untreated, advanced non-small cell lung cancer (NSCLC).

Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC

Dynavax Technologies

GlaxoSmithKline

Inovio Pharmaceuticals

Novavax

Their vaccines could be late to the party. But the stocks might still be big winners.

5 COVID Vaccine Stocks With Late-Stage Candidates You'll Want to Watch

AbbVie

There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors.

AbbVie's Pain Is Sanofi's and Regeneron's Gain

Sanofi's Covid vaccine is now in its Phase 3 trial, and the pharmaceutical company says results could come by the end of the year.

How a Covid Vaccine Could Lift Sanofi's Stock

Telesis Bio Inc

Sanofi completes acquisition of Translate Bio, accelerating the application of mRNA in new vaccines and therapeutics

NEW YORK, Sept. 9, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Kadmon Holdings, Inc. (NASDAQ: KDMN) and its board of directors concerning the proposed acquisition of the company by Sanofi (NASDAQ: SNY).

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Kadmon Holdings, Inc.

Johnson & Johnson

Pfizer

GlaxoSmithKline PLC ( GSK , Financial) is forecasted to carve out more than 25% of a vaccine market that is expected to reach $10.5 billion by 2030. FiercePharma repotrted three other members of big pharma are also in line to be rewarded for developing a shot for respiratory syncytial virus, with Pfizer Inc. ( PFE , Financial) raking in $2.1 billion, Johnson & Johnson ( JNJ , Financial) adding $1.7 billion to its top line and Sanofi SA ( SNY , Financial) pocketing $1.2 billion.

Glaxo, Pfizer, J&J and Sanofi Expected to Grab Biggest Shares of RSV Vaccine Business

Sanofi's (SNY) rilzabrutinib fails to meet the primary endpoint in a phase III study. It was added to its portfolio following the acquisition of Principia Biopharma last year.

Sanofi (SNY) Skin Disorder Drug Misses Goal in Phase III Study

Sanofi SA's (NASDAQ: SNY) BTK inhibitor, rilzabrutinib, has flunked its first major clinical test. Rilzabrutinib was Principia Biopharma Inc's one of the key candidates that Sanofi acquired last year for $3.68 billion.

Sanofi's BTK Inhibitor Disappoints In Phase 3 Autoimmune Disease Trial

Sanofi provides update on Phase 3 study evaluating rilzabrutinib for the treatment of pemphigus

Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business.

Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock

French drugmaker Sanofi is buying Kadmon, the U.S. biopharmaceutical company, for a total equity value of $1.9 billion.

Kadmon Stock Soars as Sanofi Buys U.S. Biotech for $1.9 Billion

Underlining the focus on inorganic growth, French pharma giant Sanofi (NASDAQ: SNY) announced a big-ticket acquisition just a month after another billion-dollar deal. Sanofi-Kadmon Deal Terms: Sanofi announced Wednesday it has agreed to acquire New York-based biopharma Kadmon Holdings, Inc. (NASDAQ: KDMN) in a $1.9 billion all-cash deal.

Sanofi's $1.9 Billion Bet On Kadmon: What You Need to Know

French pharmaceutical major Sanofi SA said Wednesday that it has entered into a definitive agreement to acquire U.S.-based biopharmaceutical company Kadmon Holdings Inc.

Sanofi to acquire U.S. biopharmaceutical group Kadmon in $1.9 billion deal

French drugmaker Sanofi SA has agreed to buy U.S. biopharmaceutical company Kadmon Holdings Inc in a $1.9 billion deal, the companies said on Wednesday.

France's Sanofi to buy U.S. biopharma firm Kadmon in $1.9 billion deal

Amazon

Aspen Technology Inc

Alibaba

Bayer AG

Baidu

Anheuser-Busch InBev

Campbell Soup

Enterprise Products Partners

Imperial Brands PLC

Intel

Kellogg

Lockheed Martin

Merck

Polaris

Reckitt Benckiser Group PLC

Roche Holding AG

Tencent Holdings Limited

Western Union

Yum China Hlds

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Wide-Moat Stocks On Sale - The September 2021 Heat Map

Ascendis Pharma

Cara Therapeutics

Jazz Pharmaceuticals

Sesen Bio Inc.

August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New molecular entity approvals – a measure of innovation in the biopharma sector – numbered four for the month, taking the total for the year to 36, two less than relative to the same period in 2020.

News for Sanofi Stock (SNY)